These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 19910392)

  • 41. Lenalidomide: the emerging role of a novel targeted agent in malignancies.
    Kalmadi S; Baz R; Mahindra A
    Drugs Today (Barc); 2007 Feb; 43(2):85-95. PubMed ID: 17353946
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clonal evolution in myelodysplastic syndromes with isolated del(5q): the importance of genetic monitoring.
    Jädersten M; Karsan A
    Haematologica; 2011 Feb; 96(2):177-80. PubMed ID: 21282717
    [No Abstract]   [Full Text] [Related]  

  • 43. Lenalidomide induces remission and mixed quantitative chimerism fluctuations in refractory and relapsed myeloid malignancy with del (5).
    Dumas PY; Pigneux A; Tabrizi R; Milpied N
    Leuk Res; 2010 Nov; 34(11):e302-3. PubMed ID: 20650527
    [No Abstract]   [Full Text] [Related]  

  • 44. Response to lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2 V617F mutation.
    Azaceta G; Calasanz MJ; Dourdil V; Bonafonte E; Izquierdo I; Palomera L
    Leuk Lymphoma; 2010 Oct; 51(10):1941-3. PubMed ID: 20846100
    [No Abstract]   [Full Text] [Related]  

  • 45. Lenalidomide: new drug. Myeloma: many questions remain unanswered.
    Prescrire Int; 2008 Dec; 17(98):230-2. PubMed ID: 19422142
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment of hematologic neoplasms with new immunomodulatory drugs (IMiDs).
    Wiernik PH
    Curr Treat Options Oncol; 2009 Apr; 10(1-2):1-15. PubMed ID: 19016330
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings.
    Stadtmauer EA; Lonial S; Vesole DH; Abonour R; Alsina M; Badros A; Comenzo R; Durie B; Giralt S; Hussein M; Jakubowiak A; Mehta J; Niesvizky R; Orlowski R; Siegel D; Singhal S; Vescio R; Wang M; Zangari M; Munshi NC
    Clin Adv Hematol Oncol; 2007 Oct; 5(10 Suppl 15):7-19, quiz 21-2. PubMed ID: 18000495
    [No Abstract]   [Full Text] [Related]  

  • 48. Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide.
    Kelaidi C; Park S; Brechignac S; Mannone L; Vey N; Dombret H; Aljassem L; Stamatoullas A; Adès L; Giraudier S; de Botton S; Raynaud S; Lepelley P; Picard F; Leroux G; Daniel MT; Bouscary D; Dreyfus F; Fenaux P;
    Leuk Res; 2008 Jul; 32(7):1049-53. PubMed ID: 18191202
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunomodulatory drugs.
    Crane E; List A
    Cancer Invest; 2005; 23(7):625-34. PubMed ID: 16305990
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Lenalidomide. Treatment of multiple myeloma].
    Musch A
    Med Monatsschr Pharm; 2008 Jan; 31(1):4-8; quiz 9-10. PubMed ID: 18522014
    [No Abstract]   [Full Text] [Related]  

  • 51. Inhibition of the mevalonate pathway potentiates the effects of lenalidomide in myeloma.
    van der Spek E; Bloem AC; Lokhorst HM; van Kessel B; Bogers-Boer L; van de Donk NW
    Leuk Res; 2009 Jan; 33(1):100-8. PubMed ID: 18621417
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Lenalidomide in multiple myeloma.
    Sirohi B; Powles R
    Expert Rev Anticancer Ther; 2009 Nov; 9(11):1559-70. PubMed ID: 19895240
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The immunomodulatory agents lenalidomide and thalidomide for treatment of the myelodysplastic syndromes: a clinical practice guideline.
    Leitch HA; Buckstein R; Shamy A; Storring JM
    Crit Rev Oncol Hematol; 2013 Feb; 85(2):162-92. PubMed ID: 22901762
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Health-related quality of life outcomes of lenalidomide in transfusion-dependent patients with Low- or Intermediate-1-risk myelodysplastic syndromes with a chromosome 5q deletion: results from a randomized clinical trial.
    Revicki DA; Brandenburg NA; Muus P; Yu R; Knight R; Fenaux P
    Leuk Res; 2013 Mar; 37(3):259-65. PubMed ID: 23273538
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hematologic and cytogenetic response to lenalidomide monotherapy in acute myeloid leukemia arising from JAK2(V617F) positive, del(5)(q13q33) myelodysplastic syndrome.
    Mesa RA; Tefferi A; Li CY; Steensma DP
    Leukemia; 2006 Nov; 20(11):2063-4. PubMed ID: 16990762
    [No Abstract]   [Full Text] [Related]  

  • 56. Pathophysiology and treatment of the myelodysplastic syndrome with isolated 5q deletion.
    Jädersten M
    Haematologica; 2010 Mar; 95(3):348-51. PubMed ID: 20207839
    [No Abstract]   [Full Text] [Related]  

  • 57. Cutaneous adverse reactions to lenalidomide.
    Imbesi S; Allegra A; Calapai G; Musolino C; Gangemi S
    Allergol Immunopathol (Madr); 2015; 43(1):88-91. PubMed ID: 24998775
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lenalidomide: a new agent for patients with relapsed or refractory multiple myeloma.
    Tariman JD
    Clin J Oncol Nurs; 2007 Aug; 11(4):569-74. PubMed ID: 17723971
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Thalidomide and lenalidomide in the treatment of multiple myeloma.
    Kumar S; Rajkumar SV
    Eur J Cancer; 2006 Jul; 42(11):1612-22. PubMed ID: 16750621
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Lenalidomide: second cancers.
    Prescrire Int; 2012 May; 21(127):130. PubMed ID: 22844687
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.